You just read:

Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease

News provided by

Protalix BioTherapeutics, Inc.

Feb 06, 2020, 06:50 ET